Eyegate Pharm Wts (EYEGW) 0.50 $EYEGW
Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Thu Jan 14, 8:49AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial Capital Markets' 12 Annual Conference, being held January 17-20, 2016 in Sandpiper Bay, Florida.
EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Aug 05, 12:30PM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company", a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced underwritten public offering of 1,176,470 shares of common stock, and warrants to purchase an aggregate of up to 1,176,470 shares of common stock at a combined offering price of $8.50, before underwriting discounts and commissions. The warrants have an exercise price of $10.62 per share, are immediately exercisable, and expire on August 5, 2020. At the closing of the offering, the Company also issued and sold additional warrants to purchase up to 176,470 shares of common stock in connection with the full exercise of the underwriters' over-allotment option to purchase additional warrants. The underwriters have 45 days to exercise an over-allotment option to purchase an additional 176,470 shares of common stock.
EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
EyeGate Pharmaceuticals anticipates USD10m from public offering of common stock and warrants
M2 - Fri Jul 31, 4:25AM CDT
Pharmaceutical company EyeGate Pharmaceuticals (NASDAQ:EYEGW) said on Thursday that it has priced its public offering of common stock and warrants to purchase shares of its common stock at a combined price of USD8.50 per one share of common stock and warrant to purchase one share of common stock.
EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Jul 30, 5:08PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company", a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the pricing of an underwritten public offering of 1,176,470 shares of its common stock and warrants to purchase up to 1,176,470 shares of its common stock, at a combined price to the public of $8.50 per one share of common stock and warrant to purchase one share of common stock. The warrants have a per share exercise price of $10.62, are exercisable immediately, and expire five years from the date of issuance. The gross proceeds to EyeGate from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. As a result of the offering, the Company's common stock and warrants will become listed on the NASDAQ Capital Market and will trade separately under the ticker symbols "EYEG" and "EYEGW," respectively, beginning on July 31, 2015. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 176,470 shares of common stock and/or warrants to purchase up to 176,470 shares of our common stock. The offering is expected to close on August 5, 2015, subject to customary closing conditions.
EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Thu Jan 14, 8:49AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial Capital Markets' 12 Annual Conference, being held January 17-20, 2016 in Sandpiper Bay, Florida. EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Aug 05, 12:30PM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced underwritten public offering of 1,176,470 shares of common stock, and warrants to purchase an aggregate of up to 1,176,470 shares of common stock at a combined offering price of $8.50, before underwriting discounts and commissions. The warrants have an exercise price of $10.62 per share, are immediately exercisable, and expire on August 5, 2020. At the closing of the offering, the Company also issued and sold additional warrants to purchase up to 176,470 shares of common stock in connection with the full exercise of the underwriters' over-allotment option to purchase additional warrants. The underwriters have 45 days to exercise an over-allotment option to purchase an additional 176,470 shares of common stock. EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
EyeGate Pharmaceuticals anticipates USD10m from public offering of common stock and warrants
M2 - Fri Jul 31, 4:25AM CDT
Pharmaceutical company EyeGate Pharmaceuticals (NASDAQ:EYEGW) said on Thursday that it has priced its public offering of common stock and warrants to purchase shares of its common stock at a combined price of USD8.50 per one share of common stock and warrant to purchase one share of common stock.
EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Jul 30, 5:08PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the pricing of an underwritten public offering of 1,176,470 shares of its common stock and warrants to purchase up to 1,176,470 shares of its common stock, at a combined price to the public of $8.50 per one share of common stock and warrant to purchase one share of common stock. The warrants have a per share exercise price of $10.62, are exercisable immediately, and expire five years from the date of issuance. The gross proceeds to EyeGate from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. As a result of the offering, the Company's common stock and warrants will become listed on the NASDAQ Capital Market and will trade separately under the ticker symbols "EYEG" and "EYEGW," respectively, beginning on July 31, 2015. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 176,470 shares of common stock and/or warrants to purchase up to 176,470 shares of our common stock. The offering is expected to close on August 5, 2015, subject to customary closing conditions. EYEG: 1.62 (+0.06), EYEGW: 0.50 (-0.17)
